Holen Sie sich die Stockscreener-App
2.99
8.33%
0.23
Handel nachbörslich:
3.00
0.010
+0.33%
Schlusskurs vom Vortag:
$2.76
Offen:
$2.81
24-Stunden-Volumen:
164.92K
Relative Volume:
0.67
Marktkapitalisierung:
$129.36M
Einnahmen:
$81.06M
Nettoeinkommen (Verlust:
$-55.55M
KGV:
-2.6228
EPS:
-1.14
Netto-Cashflow:
$-47.98M
1W Leistung:
+18.65%
1M Leistung:
+3.46%
6M Leistung:
-47.08%
1J Leistung:
-44.32%
1-Tages-Spanne:
$2.78
$3.00
1-Wochen-Bereich:
$2.3998
$3.00
52-Wochen-Spanne:
$2.03
$8.45
Sight Sciences Inc Stock (SGHT) Company Profile
Firmenname
Sight Sciences Inc
Sektor
Branche
Telefon
(415) 889-0550
Adresse
4040 CAMPBELL AVE,, MENLO PARK
Vergleichen Sie SGHT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
2.99 | 129.36M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-11-04 | Herabstufung | Lake Street | Buy → Hold |
| 2024-08-21 | Eingeleitet | Lake Street | Buy |
| 2023-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-09-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-08-24 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-04 | Eingeleitet | Needham | Hold |
| 2022-07-26 | Eingeleitet | Stifel | Hold |
| 2022-02-03 | Eingeleitet | William Blair | Outperform |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Sight Sciences Inc Aktie (SGHT) Neueste Nachrichten
Sight Sciences appoints new board member By Investing.com - Investing.com India
Sight Sciences appoints new board member - Investing.com
Sight Sciences Appoints Gary Burbach to its Board of Directors - The Manila Times
Sight Sciences Strengthens Board with Medtech Veteran as Glaucoma, Dry Eye Markets Transform - Stock Titan
Sight Sciences Launches OMNI® Edge Surgical System to Enhance Glaucoma Treatment - Nasdaq
Sight Sciences to Debut OMNI® Edge Surgical System at the - GlobeNewswire
Sight Sciences Unveils OMNI Edge: Next-Gen Glaucoma Surgery System with 2X Capacity | SGHT Stock News - Stock Titan
Sight Sciences, Inc. (NASDAQ:SGHT) Shares Acquired by American Century Companies Inc. - Defense World
Sight Sciences (NASDAQ:SGHT) Earns Hold Rating from Needham & Company LLC - Defense World
Sight sciences CTO David Badawi sells $15,081 in stock - MSN
April 2025's Top Penny Stocks To Watch - simplywall.st
Sight Sciences, Inc. (NASDAQ:SGHT) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Sight Sciences at 24th Annual Needham Conference: Strategic Growth Insights - Investing.com Canada
Sight sciences chief commercial officer sells $11,641 in stock By Investing.com - Investing.com India
Sight Sciences stock hits 52-week low at $2.13 amid market challenges - Investing.com
Sight sciences chief commercial officer sells $11,641 in stock - Investing.com
Sight sciences CEO Paul Badawi sells shares worth $55,672 By Investing.com - Investing.com Australia
Sight sciences CTO David Badawi sells $13,771 in common stock By Investing.com - Investing.com India
Sight Sciences CFO Alison Bauerlein sells shares worth $44,787 By Investing.com - Investing.com Australia
Sight Sciences CFO Alison Bauerlein sells shares worth $44,787 - Investing.com
Sight sciences CTO David Badawi sells $13,771 in common stock - Investing.com
Sight Sciences chief legal officer sells $21,693 in stock - Investing.com
Sight Sciences chief legal officer sells $21,693 in stock By Investing.com - Investing.com UK
Sight Sciences Executives Sell Shares to Cover Tax Liabilities - TradingView
Sight Sciences stock hits 52-week low at $2.13 amid market challenges By Investing.com - Investing.com South Africa
Sight Sciences, Inc. (NASDAQ:SGHT) Short Interest Update - Defense World
Charles Schwab Investment Management Inc. Raises Stock Position in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences, Inc. (NASDAQ:SGHT) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st
Sight sciences chief legal officer sells shares worth $19,250 - MSN
Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th - GlobeNewswire
Key Investor Updates Coming: Sight Sciences Takes Center Stage at Major Healthcare Conference - Stock Titan
RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Sight Sciences, Inc. (NASDAQ:SGHT) Receives Average Recommendation of “Hold” from Analysts - Defense World
Sight sciences EVP Manohar Raheja buys $53,250 in stock By Investing.com - Investing.com Australia
Sight sciences EVP Manohar Raheja buys $53,250 in stock - Investing.com India
Piper Sandler Cuts Sight Sciences (NASDAQ:SGHT) Price Target to $3.50 - Defense World
Sight Sciences’ (SGHT) Hold Rating Reiterated at Needham & Company LLC - Defense World
Compared to Estimates, Sight Sciences (SGHT) Q4 Earnings: A Look at Key Metrics - MSN
Lake Street Capital Has Lowered Expectations for Sight Sciences (NASDAQ:SGHT) Stock Price - Defense World
Stifel Nicolaus Has Lowered Expectations for Sight Sciences (NASDAQ:SGHT) Stock Price - Defense World
Earnings call transcript: Sight Sciences Q4 2024 results miss forecasts By Investing.com - Investing.com Australia
Actinic Keratosis Market Forecast 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Treatment, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Sight Sciences Inc. (SGHT) reports earnings - Quartz
Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results, Initiates Full Year 2025 Financial Guidance - Vision Monday
Sight Sciences Faces Headwinds in Glaucoma and Dry Eye Markets, Hold Rating Maintained - TipRanks
Sight Sciences’ Earnings Call: Cautious Optimism Amid Challenges - TipRanks
Sight Sciences price target lowered to $3.50 from $5.50 at Piper Sandler - TipRanks
Stifel cuts Sight Sciences price target to $4, maintains Buy rating By Investing.com - Investing.com South Africa
Stifel cuts Sight Sciences price target to $4, maintains Buy rating - Investing.com
Sight Sciences Stock Hits 52-Week Low at $2.27 Amid Market Challenges - Investing.com India
Sight Sciences Stock Hits 52-Week Low at $2.27 Amid Market Challenges By Investing.com - Investing.com South Africa
Finanzdaten der Sight Sciences Inc-Aktie (SGHT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):